Skip to main
MIRM
MIRM logo

MIRM Stock Forecast & Price Target

MIRM Analyst Ratings

Based on 16 analyst ratings
Buy
Strong Buy 38%
Buy 63%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Mirum Pharmaceuticals Inc. has demonstrated strong financial performance with Livmarli's net sales revenue reaching $64.1 million in Q4 2024, reflecting an 8.4% increase from Q3 2024 and a significant 54.5% growth compared to Q4 2023. The company anticipates continued revenue growth in 2025, particularly from Livmarli's progressive familial intrahepatic cholestasis indication, alongside positive developments in its other product lines, including volixibat and its bile acid product portfolio. Additionally, Mirum is positioned as a cash-flow positive commercial-stage entity, with multiple clinical milestones that present further upside potential, reinforcing a favorable outlook for future performance.

Bears say

Mirum Pharmaceuticals faces several significant risks that contribute to a negative outlook for its stock, including the possibility of sales growth for its products, LIVMARLI and volixibat, falling short of expectations and the potential for regulatory setbacks. The company reported a net loss of $87.9 million for FY2024, driven by high research and development, and selling, general and administrative expenses, which may hinder its ability to fund operations and necessitate additional capital raises with possible share dilution. Furthermore, the company must demonstrate differentiation within its pipeline to ensure commercial uptake, as failure to do so, combined with uncertainties surrounding clinical trial outcomes and safety issues, could jeopardize future profitability.

MIRM has been analyzed by 16 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 63% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Mirum Pharmaceuticals Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Mirum Pharmaceuticals Inc (MIRM) Forecast

Analysts have given MIRM a Buy based on their latest research and market trends.

According to 16 analysts, MIRM has a Buy consensus rating as of Aug 2, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $59.19, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $59.19, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Mirum Pharmaceuticals Inc (MIRM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.